NCT05623722 Erector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury
| NCT ID | NCT05623722 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jing Cai, MD |
| Condition | Sepsis |
| Study Type | INTERVENTIONAL |
| Enrollment | 116 participants |
| Start Date | 2022-12-29 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 116 participants in total. It began in 2022-12-29 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective, multicenter, parallel-group, open-label, randomized controlled clinical trial. Sepsis is defined as organ dysfunction induced by infections. And sepsis and gastrointestinal injury can be the leading cause for each other. Our previous study showed erector spinae plane block improved the organ dysfunctions in patients with AGI. The aim of the clinical trial is to investigate erector pinae plane block improves the organ dysfunction in septic patients with acute gastrointestinal injury.
Eligibility Criteria
Inclusion Criteria: * Septic patients with acute gastrointestinal injury grade II or III; * Age over 18 years; * Expected to stay in the ICU for at least 3 days or longer; Exclusion Criteria: * Mean arterial pressure less than 65 mmHg after fluid resuscitation, or requirement for an intravenous norepinephrine dose of greater than 0.5 µg/kg/min to maintain a normal mean arterial pressure; * Heart rates less than 50 beats/min, or concomitant with moderate-to-severe atrioventricular block without a pacemaker; * Contraindications for erector spinae plane blocks, including infection of the puncture site, spinal diseases or immobilization; * Primary gastrointestinal disorders requiring a surgical procedure, such as mechanical intestinal obstruction, massive gastrointestinal hemorrhage, and gastrointestinal perforation; * Gastrointestinal operation within one week before enrollment; * Neuromuscular disorders; * Coagulation abnormalities：activated prothrombin time or prothrombin time is prolonged with 2 folds, or platelet count less than 50×109/L; * End-stage malignant tumor or cachexia; * History of allergy to amide anesthetics; * Known pregnancy;
Contact & Investigator
Jing Cai
PRINCIPAL INVESTIGATOR
Department of Intensive Care Medicine, Zhujiang Hospital, Southern Medical University
Frequently Asked Questions
Who can join the NCT05623722 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05623722 currently recruiting?
Yes, NCT05623722 is actively recruiting participants. Contact the research team at caijing78@hotmail.com for enrollment information.
Where is the NCT05623722 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT05623722 clinical trial?
NCT05623722 is sponsored by Jing Cai, MD. The principal investigator is Jing Cai at Department of Intensive Care Medicine, Zhujiang Hospital, Southern Medical University. The trial plans to enroll 116 participants.